Insulin resistance reverses despite weight gain with pan-PPAR agonism, revealing its plasma molecular correlates in type 2 diabetes

In the ChiHOPE cohort of 835 type 2 diabetes patients, 53% of chiglitazar-treated participants with baseline HOMA-IR-defined insulin resistance no longer met the IR threshold despite BMI rising.

• Why it matters: Insulin resistance and body weight are tightly linked in T2D, making it difficult to disentangle their molecular correlates in observational studies. Pan-PPAR agonism tests whether insulin sensitivity can improve while weight increases.
• What they did: The study integrated plasma metabolomics and proteomics to build a molecular estimate of HOMA-IR, then compared it with routine clinical measures and HOMA-IR classification. It also assessed how this molecular estimate changed with chiglitazar versus placebo and sitagliptin.
• The result: The molecular estimate outperformed routine measures, disagreed with HOMA-IR classification in 27% of patients, and with chiglitazar it fell despite weight gain, showing lower proteoglycan 4 and higher glutamine and glycine. This implies circulating IR markers can improve without weight loss.

AI summary of the abstract · may contain errors · not medical advice · read the paper.